Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.

Sixth Street Specialty Lending, Inc.

PJT Partners Inc., an investment bank, provides various strategic and capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments worldwide. It offers advisory services to clients on various transactions, including mergers and acquisitions (M&A), spin-offs, activism defense, contested M&A, joint ventures, minority investments, and divestitures. The company also advises private and public company boards and management teams on strategies for building productive investor relationships with a focus on shareholder engagement; and strategic investor relations; environmental, social, and governance matters; and other investor-related matters. In addition, it provides advisory services related to debt and acquisition financings; structured product offerings; public equity raises, including initial public offering and SPAC offerings; and private capital raises for early and later stage companies, as well as other capital structure related matters. Further, the company offers advisory services in restructurings and recapitalizations; and serving a range of companies, creditors, and financial sponsors on liability management and related capital raise transactions, including exchanges, recapitalizations, reorganizations, debt repurchases, and distressed mergers and acquisitions. Additionally, it provides private fund advisory and fundraising services for a range of investment strategies; and advisory services to GPs and LPs on liquidity and other structured solutions in the secondary market. The company was formerly known as Blackstone Advisory Inc. and changed its name to PJT Partners Inc. in March 2015. PJT Partners Inc. was incorporated in 2014 and is headquartered in New York, New York.

PJT Partners Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics, Inc.

Bogota Financial Corp. operates as the bank holding company for Bogota Savings Bank that provides banking products and services in the United States. It offers deposit accounts, including demand accounts, savings accounts, money market accounts, and certificate of deposit accounts. The company also provides one-to four-family residential real estate loans, and commercial real estate and multi-family loans, as well as consumer loans, such as home equity loans and lines of credit, commercial and industrial loans, and construction loans; and buys, sells, and holds investment securities. It operates through various offices located in Bogota, Hasbrouck Heights, Newark, Oak Ridge, Parsippany, and Teaneck, as well as through a loan production office in Spring Lake, New Jersey. The company was founded in 1893 and is based in Teaneck, New Jersey. Bogota Financial Corp. operates as a subsidiary of Bogota Financial, MHC.

Bogota Financial Corp.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals Inc.

Rapid7, Inc. provides cyber security solutions. The company offers a cloud-native insight platform that enables customers to create and manage analytics-driven cyber security risk management programs. Its platform includes InsightIDR, an incident detection and response solution; InsightCloudSec, a solution that integrates posture management, workload protection, infrastructure entitlements management, infrastructure-as-code security, and Kubernetes protection; InsightVM, a vulnerability risk management solution that is designed to provide a way to collect vulnerability data, prioritize risk, and automate remediation; InsightAppSec, which provides application security testing that analyzes web applications for security vulnerabilities; and InsightConnect, a security orchestration and automation response solution that is used by security professionals. The company's other products include DivvyCloud, a cloud security posture management solution; Nexpose, an on-premises version of company's vulnerability risk management solution; AppSpider, an on-premises version of company's application security testing solution; and Metasploit, a penetration testing software solution, as well as professional services. It offers its products through term or perpetual software licenses, cloud-based subscriptions, and managed services. The company serves customers in a range of industries, including technology, energy, financial services, healthcare and life sciences, manufacturing, media and entertainment, retail, education, real estate, transportation, government, and professional services industries through sales teams, and indirect channel partner relationships, as well as directly in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Rapid7, Inc.

LightPath Technologies, Inc. designs, develops, manufactures, and distributes optical components and assemblies. The company offers precision molded glass aspheric optics, molded and diamond-turned infrared aspheric lenses, and other optical components used to produce products that manipulate light. Its products are used in defense products, medical devices, laser aided industrial tools, automotive safety applications, barcode scanners, optical data storage, hybrid fiber coax datacom, telecommunications, machine vision and sensors, and other industries. The company sells its products directly to customers in North America, Europe, and Asia, as well as through distributors and catalogs in the United States and internationally. LightPath Technologies, Inc. was founded in 1985 and is headquartered in Orlando, Florida.

LightPath Technologies, Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc.

RXO provides truckload freight transportation brokerage in the United States. The company, through a proprietary digital freight marketplace, offers access to truckload capacity and complementary brokered services of managed transportation, last mile, and freight forwarding. The company is based in Charlotte, North Carolina.

RXO, Inc.

As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.

Atlantic International Corp.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

Lucid Group, Inc. a technology and automotive company, develops electric vehicle (EV) technologies. The company designs, engineers, and builds electric vehicles, EV powertrains, and battery systems. As of December 31, 2021, it operates twenty retail studios in the United States. Lucid Group, Inc. was founded in 2007 and is headquartered in Newark, California.

Lucid Group, Inc.

Optex Systems Holdings, Inc. manufactures and sells optical sighting systems and assemblies primarily for the U.S. department of defense, foreign military applications, and commercial markets in the United States. It offers periscopes, such as laser and non-laser protected plastic and glass periscopes, electronic M17 day/thermal periscopes, and vision blocks; sighting systems, including back up sights, digital day and night sighting systems, M36 thermal periscope, unity mirrors, optical weapon system support and maintenance, and commander weapon station sights; howitzers comprising M137 telescope, M187 mount, M119 aiming device, XM10 and aiming circles; and applied optics center consisting of laser filter units, laser filter interface, optical assemblies, day windows, binoculars, and specialty thin film coatings, as well as other products, such as muzzle reference systems, binoculars, collimators, optical lenses and elements, and windows. The company also provides various periscope configurations, rifle and surveillance sights, and night vision optical assemblies. Its products are installed on various types of U.S. military land vehicles, such as the Abrams, Bradley, and Stryker families of fighting vehicles, as well as light armored and armored security vehicles. The company offers its products directly to the federal government, prime contractors, and foreign governments. Optex Systems Holdings, Inc. was founded in 1987 and is headquartered in Richardson, Texas. Optex Systems Holdings, Inc operates as a subsidiary of Sileas Corporation.

Optex Systems Holdings, Inc

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for utility, commercial and industrial, and renewable energy markets in the United States. It offers stationary battery storage solutions. The company's flagship product is the Eos Znyth DC battery system designed to meet the requirements of the grid-scale energy storage market. Eos Energy Enterprises, Inc. was founded in 2008 and is headquartered in Edison, New Jersey.

Eos Energy Enterprises, Inc.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals, Inc.

SKYX Platforms Corp. provides a series of safe-smart platform technologies. The company's first-generation technologies enable light fixtures, ceiling fans, and other electrically wired products to be installed into a ceiling's electrical outlet box; and second-generation technology provides a platform that is designed to enhance safety and lifestyle of homes and other buildings. It offers power-plugs; universal power-plug and receptacle products; and smart products. The company was formerly known as SQL Technologies Corp. and changed its name to SKYX Platforms Corp. in June 2022. SKYX Platforms Corp. was incorporated in 2004 and is headquartered in Pompano Beach, Florida.

SKYX Platforms Corp.

Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.

Nutex Health, Inc.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Discover the most dynamic companies of the U.S. market, driving exceptional revenue growth across industries. This curated list highlights market leaders and emerging innovators achieving rapid expansion through cutting-edge technology, strategic execution, and customer-driven innovation.

From disruptive startups to established corporations, these high-growth organizations are redefining their sectors and capturing investor attention with their sustained financial momentum and scalable business models.

#	Company	Industry	Price	Vs 52W High	Market Cap	Analyst Target	P/E	Dividend	DCF	Score	Value	Profit	Growth	Health
1	Crinetics Pharmaceuticals, Inc... CRNX NASDAQ US	Biotechnology	$43.44 -1.38 (-3.09%)	-25.09% vs $57.99	$4.38 B	$84.49	-9.27	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
2	Sixth Street Specialty Lending... TSLX NYSE US	Asset Managemen…	$18.19 -0.89 (0.43%)	-27.73% vs $25.17	$1.82 B	-	-4.87 K	$1.90	-	0 / 100	- / 100	- / 100	- / 100	- / 100
3	PJT Partners Inc. PJT NYSE US	Financial - Cap…	$151.63 0.13 (0.19%)	-22.49% vs $195.62	$3.75 B	$160.80	0.08	$1.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
4	TG Therapeutics, Inc. TGTX NASDAQ US	Biotechnology	$29.53 0.08 (2.49%)	-36.47% vs $46.48	$4.52 B	$39.00	11.74	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
5	Bogota Financial Corp. BSBK NASDAQ US	Banks - Regiona…	$8.56 -0.04 (1.64%)	-9.89% vs $9.50	$109.62 M	-	0.16	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
6	Aurinia Pharmaceuticals Inc. AUPH NASDAQ CA	Biotechnology	$14.40 -0.08 (-5.42%)	-12.94% vs $16.54	$1.88 B	$16.00	19.47	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
7	Rapid7, Inc. RPD NASDAQ US	Software - Infr…	$6.57 0.09 (1.18%)	-81.62% vs $35.75	$470.15 M	$17.17	0.32	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
8	LightPath Technologies, Inc. LPTH NASDAQ US	Hardware, Equip…	$12.00 -0.96 (-9.00%)	-21.26% vs $15.24	$502.57 M	$14.73	-0.05	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
9	Beam Therapeutics Inc. BEAM NASDAQ US	Biotechnology	$27.59 0.99 (-3.33%)	-24.29% vs $36.44	$2.83 B	$37.05	-6.00	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
10	RXO, Inc. RXO NYSE US	Trucking	$15.76 0.52 (-4.53%)	-28.91% vs $22.17	$2.22 B	$15.14	-21.33	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
11	Atlantic International Corp. ATLN NASDAQ US	Medical - Diagn…	$2.76 -0.01 (NaN%)	-57.54% vs $6.50	$185.33 M	-	-1.65	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
12	CorMedix Inc. CRMD NASDAQ US	Biotechnology	$7.03 -0.02 (23.01%)	-59.67% vs $17.43	$578.31 M	$13.88	5.43	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
13	Lucid Group, Inc. LCID NASDAQ US	Auto - Manufact…	$9.55 0.36 (2.00%)	-73.40% vs $35.90	$3.33 B	$13.18	-3.26	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
14	Optex Systems Holdings, Inc OPXS NASDAQ US	Aerospace & Def…	$11.84 0.38 (NaN%)	-33.33% vs $17.76	$101.74 M	-	0.00	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
15	Eos Energy Enterprises, Inc. EOSE NASDAQ US	Electrical Equi…	$10.70 0.31 (4.36%)	-46.12% vs $19.86	$2.65 B	$15.37	-2.77	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
16	Nanobiotix S.A. NBTX NASDAQ FR	Biotechnology	$24.78 0.85 (-1.36%)	-18.35% vs $30.35	$1.23 B	$26.00	-3.79	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
17	Apellis Pharmaceuticals, Inc. APLS NASDAQ US	Biotechnology	$22.28 -0.35 (-0.29%)	-26.90% vs $30.48	$2.75 B	$28.74	63.40	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
18	SKYX Platforms Corp. SKYX NASDAQ US	Electrical Equi…	$2.10 0.06 (6.67%)	-36.17% vs $3.29	$242.84 M	-	-3.53	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
19	Nutex Health, Inc. NUTX NASDAQ US	Medical - Healt…	$101.08 -5.31 (-3.81%)	-47.65% vs $193.07	$593.71 M	$205.00	6.07	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100
20	Ascendis Pharma A/S ASND NASDAQ DK	Biotechnology	$225.00 -1.78 (2.25%)	-7.02% vs $242.00	$13.28 B	$305.50	-48.92	$0.00	-	0 / 100	- / 100	- / 100	- / 100	- / 100

Fastest Growing Companies By Revenue